Has anyone knowledge about this drug? Its from Japan, I suppose. And it can be “a new better version” of metformin.
Maybe someone knows any reviews from some smart guys like Johnson or Sinclair or Kaeberlein?
1 Like
The following analysis evaluates the scientific and clinical evidence for Imeglimin (Twymeeg), specifically focusing on its potential impact on healthspan and longevity beyond its approved use for Type 2 Diabetes (T2D).
Executive Summary
Current Status: Imeglimin is a first-in-class oral medication (“Glimin”) approved in Japan for T2D.1
Longevity Verdict: Promising but unproven. While it shares critical mechanistic pathways with Metformin (AMPK activation) and NAD+ precursors (mitochondrial bioenergetics), clinical evidence is currently limited to glycemic control and safety. No human data currently supports lifespan extension, and large-scale cardiovascular outcome trials (CVOTs) are lacking.
Key Differentiator: Unlike Metformin, which inhibits mitochondrial Complex I “blindly,” Imeglimin appears to modulate Complex I while correcting Complex III dysfunction, potentially reducing Reactive Oxygen Species (ROS) without the metabolic rigidity (e.g., lactate risk) sometimes seen with biguanides.2+1
1. Mechanism of Action: The Longevity Case
Imeglimin’s primary appeal for longevity lies in its unique ability to target mitochondrial bioenergetics, the “engine room” of aging.3
-
Mitochondrial Modulation: Imeglimin acts directly on the mitochondrial respiratory chain.4
- Complex I Inhibition: Similar to Metformin, it partially inhibits Complex I.5 This creates a mild energetic stress that activates AMPK (Adenosine Monophosphate-activated Protein Kinase), a master regulator of metabolism and a key pro-longevity pathway.
- Complex III Correction: Unlike Metformin, Imeglimin reportedly corrects dysfunctional activity at Complex III.6 This is crucial because Complex III dysfunction is a major source of superoxide (ROS) generation.
- NAD+ Synthesis: Preclinical data indicates Imeglimin enhances the expression of NAMPT (Nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway.7 Elevated NAD+ levels are essential for Sirtuin activity (DNA repair, epigenetic maintenance) and generally decline with age.
- mPTP Inhibition: It inhibits the opening of the Mitochondrial Permeability Transition Pore (mPTP) .8Preventing mPTP opening protects cells from apoptotic death during stress (e.g., ischemia/reperfusion injury), suggesting potential cytoprotective effects for the heart and brain.9
2. Clinical Evidence (Human Trials)
Most high-quality data comes from the TIMES (Trials of IMeglimin for Efficacy and Safety) program in Japan.10
A. Glycemic & Metabolic Health (Proven)
- Efficacy: The TIMES 1, 2, and 3 trials demonstrated significant HbA1c reductions (monotherapy and combination).11
- Dual Mechanism: It is the only oral agent that simultaneously amplifies Glucose-Stimulated Insulin Secretion (GSIS) and improves insulin sensitivity.12 This preserves Beta-cell mass (pancreatic longevity) in preclinical models, theoretically delaying the progression of diabetes.13
B. Cardiovascular & Renal Health (Secondary/Exploratory)
-
Kidney Function: Safety has been established in patients with Chronic Kidney Disease (CKD) up to stage 3b/4.14 Small retrospective analyses suggest it may reduce proteinuria (albuminuria), a marker of kidney aging/damage, likely via endothelial protection.15
-
Cardiovascular: There are no large-scale CVOTs (like EMPA-REG for Empagliflozin) proving Imeglimin reduces heart attacks or strokes. However, it does not appear to increase CV risk.
-
Biomarkers: Recent studies have noted reductions in circulating cell-free mitochondrial DNA (a marker of systemic mitochondrial stress) and inflammatory cytokines (IL-6) in treated patients.16
C. The “Erythrocyte Lifespan” Confounder
An interesting finding from the INFINITY trial suggests Imeglimin may prolong the lifespan of red blood cells (erythrocytes) .17
- Significance: While this technically means “cellular life extension,” in a clinical context, it confounds HbA1c readings (making them artificially high because older blood cells accumulate more sugar). This requires clinicians to use other markers (like Glycated Albumin) to gauge true efficacy.
3. Preclinical Evidence (Animal/Cellular)
This is where the strongest “longevity” signal exists, though it has not yet translated to humans.
-
Organ Protection:
- Heart: In rat models of metabolic syndrome, Imeglimin improved left ventricular function and reduced fibrosis.18
- Liver: In models of MASH (Metabolic dysfunction-Associated Steatohepatitis), it reduced hepatic steatosis and fibrosis by improving mitochondrial biogenesis and fat oxidation.19
- Neuroprotection: Limited animal data suggests reduction in ischemia-induced brain damage, likely due to the mPTP inhibition mechanism mentioned above.20
4. Comparative Analysis: Imeglimin vs. Metformin
| Feature | Metformin | Imeglimin |
|---|---|---|
| Primary Target | Mitochondrial Complex I (Inhibition) | Complex I (Inhibition) + Complex III (Correction) |
| AMPK Activation | Strong | Yes (Likely similar potency) |
| NAD+ Effect | Indirect | Direct (via NAMPT upregulation) |
| ROS Production | Can increase ROS if dosage is toxic | Decreases ROS (prevents oxidative stress) |
| Gut Tolerance | Poor (Diarrhea common) | Moderate (Better tolerated than Metformin) |
| Lactate Risk | Rare but possible (Lactic Acidosis) | Lower theoretical risk (no inhibition of lactate metabolism) |
| Cost | Extremely Low | High (Patented) |
5. Critical Gaps & Risks
- No Lifespan Data: There are no studies (even in mice) demonstrating that Imeglimin extends maximum lifespan.
- Lack of Global Approval: It is currently only approved in Japan (and potentially other Asian markets).21The FDA/EMA have not approved it, largely due to corporate strategic shifts (Poxel/Sumitomo) rather than safety failures, but this limits the data pool.
- Unknown Long-term Safety: We lack the multi-decade safety data that exists for Metformin.22
Conclusion
Scientifically, Imeglimin is a “super-Metformin” candidate. Its mechanism hits the “holy trinity” of metabolic longevity: Mitochondrial quality control, ROS reduction, and NAD+ synthesis.23
Clinically , it is a robust anti-diabetic agent with a favorable safety profile.24 However, there is zero direct clinical evidence currently supporting its use as a geroprotector (anti-aging drug) in healthy humans. It remains a speculative optimization for those who cannot tolerate Metformin or wish to target mitochondrial dysfunction more specifically.